ArticleAmerican journal of translational research2026
GJB5 expression in pancreatic adenocarcinoma: prognostic significance and therapeutic implications.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the gap: moonlighting functions of connexins in cancer.Cell communication and signaling : CCS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGap junction protein 5 (GJB5) has been associated with tumorigenesis; however, its exact role in pancreatic adenocarcinoma (PAAD) remains unclear. This study investigates GJB5's expression, its functional roles in tumor progression, and its prognostic significance in PAAD.
methodsThis study used multiple bioinformatics tools, including Tissue Infiltrating Microenvironment Estimation Resource 2, University of Alabama at Birmingham Cancer, Tumor Immune System Interaction Database, Gene Expression Profiling Interactive Analysis 2, and cBioPortal. These tools were used to analyze GJB5 expression, its correlation with immune cell infiltration, and its potential as a prognostic biomarker in PAAD. Functional assays, including cell counting kit-8, colony formation, wound healing, and transwell assays, were performed to investigate the impact of GJB5 on PAAD tumor cell behaviors, including proliferation, migration, and invasion. Additionally, pathways associated with GJB5 and its interactions with the tumor microenvironment were explored.
resultsGJB5 was significantly overexpressed in PAAD tissues compared to adjacent normal tissues. Promoter hypomethylation, rather than somatic mutation, was identified as the primary mechanism driving GJB5 upregulation. Survival analysis and Cox regression models indicated that upregulated GJB5 expression is an independent prognostic factor for poor survival in patients with PAAD. Furthermore, GJB5 expression was positively correlated with immune cell infiltration in the PAAD microenvironment. Functional assays exhibited that silencing GJB5 reduced cell proliferation, migration, and invasion in PAAD cell lines.
conclusionsGJB5 is a significant prognostic biomarker for PAAD and a potential therapeutic target for reversing tumor progression, providing novel strategies for PAAD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.